Vaxxinova

Vaxxinova is a veterinary vaccine company that specializes in autogenous vaccines and proprietary technologies. Its primary offerings include patented Siderophore Receptors and Porins (SRP) technology and proprietary whole-cell autogenous biologics. Vaxxinova utilizes exclusive adjuvants for manufacturing whole-cell vaccines tailored to address specific bacterial and viral pathogens affecting livestock herds. The SRP technology induces host immunity against cell wall components called Siderophore Receptors and Porins, which transport iron, an essential nutrient for bacteria. By creating antibodies to SRPs, the vaccine deprives bacteria of iron, causing them to die. This approach targets conserved SRPs found across various bacterial species.

Vaxxinova acquired Epitopix in 2018 and Newport Laboratories in 2021, consolidating their respective expertise in SRP technology and autogenous vaccine production. The company holds two USDA establishment licenses for manufacturing veterinary biologicals. As of August 2023, Vaxxinova rebranded its US operations, integrating Newport Laboratories as a dedicated brand for custom-made vaccines and diagnostic services.

Vaxxinova operates under the umbrella of the EW Group, a family-owned conglomerate specializing in animal genetics, nutrition, and health. The EW Group has a global presence across over 100 countries. Vaxxinova has production and research facilities in multiple countries, including Germany, the Netherlands, and the US.